DEFM14A: NovaBay Pharmaceuticals to Sell Avenova Business, Dissolve Company in Effort to Maximize Stockholder Value

NovaBay Pharmaceuticals is seeking stockholder approval to sell its Avenova business and dissolve the company, aiming to distribute remaining assets to stockholders.

Summary

• NovaBay Pharmaceuticals is seeking stockholder approval for the sale of its Avenova business to PRN Physician Recommended Nutriceuticals for $9.5 million, subject to adjustments.
• The company plans to liquidate and dissolve following the sale, distributing any remaining assets to stockholders.
• The Board of Directors believes this approach maximizes stockholder value, given the company's financial challenges and limited capital.
• A special meeting is scheduled for November 22, 2024, for stockholders to vote on the asset sale and dissolution proposals.
• An alternative unsolicited offer for the Avenova business was received on September 25, 2024, and is being evaluated by the Board.
• Estimated liquidating distributions to stockholders are projected to be in the range of $0.01 to $0.91 per share, but this is subject to significant uncertainties.
• The company plans to request its common stock stop trading on the NYSE American at the Effective Time or as soon thereafter as is reasonably practicable and to initiate steps to exit from certain reporting requirements under the Exchange Act.

Sentiment

Score: 3

Explanation: The document indicates a negative outlook due to the company's financial challenges, the sale of its primary asset, and the planned dissolution. The estimated liquidating distributions are low, and there are significant risks associated with the asset sale and dissolution process.

Positives

• The asset sale provides immediate cash infusion of $9.5 million, less adjustments, to NovaBay.
• The Board of Directors is seeking to maximize stockholder value through the proposed asset sale and subsequent dissolution.
• The company has obtained a fairness opinion from Hemming Morse regarding the asset sale.
• PRN is an industry leader with a leading physician recommended nutraceutical dry eye product and a synergistic business model to the Avenova Business.

Negatives

• The Avenova business has been responsible for the majority of NovaBay's revenue since 2015, and its sale will significantly impact the company's operations.
• The estimated liquidating distributions to stockholders are subject to significant uncertainties and may be lower than projected or even zero.
• The company's common stock is likely to be delisted from the NYSE American as a result of the asset sale.
• The company will incur significant expenses in connection with the asset sale and dissolution, regardless of whether the asset sale is completed.
• The Asset Purchase Agreement limits NovaBay's ability to pursue alternatives to the asset sale.

Risks

• The asset sale is subject to various closing conditions, and there is no guarantee it will be completed.
• The company's stockholders may be liable to creditors if reserves for liabilities are inadequate.
• The Board of Directors may determine not to proceed with the dissolution, even if approved by stockholders.
• The company's directors and executive officers may have interests in the asset sale and dissolution that are different from those of stockholders.
• The company is evaluating an alternative unsolicited offer for the Avenova business, which could potentially disrupt the current agreement with PRN.

Future Outlook

The company intends to liquidate its remaining assets and distribute the proceeds to stockholders after satisfying its obligations, subject to approval by the Delaware Court of Chancery.

Management Comments

• The NovaBay Board of Directors has determined that it is in the best interests of stockholders to seek a divestiture of the Avenova Business.
• The NovaBay Board of Directors believes that effecting the Dissolution pursuant to the Plan of Dissolution is advisable and in the best interests of NovaBay and its stockholders.

Industry Context

The announcement reflects a strategic shift in the pharmaceutical industry, where companies are increasingly focusing on core assets and maximizing stockholder value through divestitures and liquidations.

Comparison to Industry Standards

• The sale of the Avenova Business and subsequent dissolution of NovaBay Pharmaceuticals can be compared to other pharmaceutical companies that have divested assets to focus on core competencies or maximize shareholder value.
• For example, Allergan's divestiture of its generics business to Teva Pharmaceuticals in 2016 for $40.5 billion allowed Allergan to focus on its branded pharmaceutical business.
• Similarly, Pfizer's spin-off of its animal health business, Zoetis, in 2013 created a separate, publicly traded company focused on animal health, allowing Pfizer to concentrate on its human pharmaceutical business.
• In terms of global benchmarks, the estimated liquidating distributions of $0.01 to $0.91 per share are relatively low compared to other pharmaceutical company liquidations, which often result in higher returns for shareholders due to the value of intellectual property and other assets.
• However, NovaBay's situation is unique due to its financial challenges and limited capital, making the asset sale and dissolution a strategic decision to maximize value in a difficult situation.

Stakeholder Impact

• Stockholders may receive liquidating distributions, but the amount is uncertain and could be low.
• Employees may be affected by the asset sale and dissolution, with potential job losses.
• Customers may experience changes in product availability and support.
• Suppliers may need to establish new relationships with the acquiring company.

Next Steps

• Stockholders will vote on the asset sale and dissolution proposals at the special meeting on November 22, 2024.
• If approved, the company will proceed with the asset sale and then liquidate its remaining assets.
• The company will seek approval from the Delaware Court of Chancery for the dissolution plan.
• The company will distribute any remaining assets to stockholders after satisfying its obligations.

Key Dates

Keywords

dissolution, Avenova, asset sale, liquidation, PRN, stockholders, NovaBay, pharmaceuticals